Back | Next |
home / stock / abus / abus message board
Subject | By | Source | When |
---|---|---|---|
$ABUS patent infringement$ MRNA /\ patent infringement | mick | investorshub | 02/16/2023 3:32:01 PM |
I AM SURPRISED NO DIVY TO SHAREHOLDERS ALL | mick | investorshub | 02/05/2023 11:58:10 PM |
THANK YOU, $ABUS | mick | investorshub | 02/05/2023 11:57:14 PM |
$ABUS Arbutus Biopharma Corporation | mick | investorshub | 02/05/2023 11:56:49 PM |
$ABUS provides 2023 roadmap: | DewDiligence | investorshub | 01/05/2023 3:22:51 PM |
Can someone remind me what we are waiting | too simple | investorshub | 12/28/2022 12:31:07 PM |
$ABUS Arbutus Biopharma Corporation | mick | investorshub | 12/18/2022 11:45:09 PM |
Maybe. | Slojab | investorshub | 12/08/2022 4:46:18 PM |
Hell Yea, here we go!!! | Little Run | investorshub | 11/02/2022 11:04:21 PM |
Order Document: 32 | Paullee | investorshub | 11/02/2022 10:09:20 PM |
$ABUS discontinues AB-836 for HBV due to safety problem: | DewDiligence | investorshub | 11/01/2022 11:13:50 PM |
$ABUS Arbutus Biopharma Corporation | mick | investorshub | 10/23/2022 6:29:07 PM |
$ABUS Arbutus Biopharma Corporation | mick | investorshub | 09/01/2022 12:12:38 AM |
Arbutus Biopharma ($ABUS) Receives a Buy from H.C. Wainwright | mick | investorshub | 08/30/2022 5:31:29 PM |
https://ih.advfn.com/stock-market/NASDAQ/arbutus-biopharma-$ABUS/stock-news/88944 | mick | investorshub | 08/30/2022 3:57:06 PM |
abus bout Arbutus | mick | investorshub | 08/30/2022 3:55:26 PM |
abus About HBV | mick | investorshub | 08/30/2022 3:54:59 PM |
abus About AB-729 | mick | investorshub | 08/30/2022 3:54:37 PM |
abus AB-729 is currently in multiple Phase 2a | mick | investorshub | 08/30/2022 3:54:12 PM |
abus We are pleased to be granted this | mick | investorshub | 08/30/2022 3:53:47 PM |
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...
At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100% of these patients 24 weeks after completing imdusiran and IFN treatment ...